{
    "class": "Abstract",
    "sources": {
        "default": {
            "displayName": "AACR",
            "longName": "American Association for Cancer Research",
            "name": "aacr",
            "url": "https://aacrjournals.org"
        }
    },
    "records": {
        "Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL Abstract#4192": {
            "url": "https://cancerres.aacrjournals.org/content/71/8_Supplement/4192",
            "year": "2011",
            "name": "Abstract 4192: Role of NF-κB regulators A20 and CARD11 in middle eastern diffuse large B cell lymphoma",
            "abstractNumber": "4192",
            "meeting": "Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL",
            "doi": "10.1158/1538-7445.AM2011-4192",
            "journalName": "Cancer Research",
            "displayName": "AACR 2011 (abstract 4192)"
        },
        "Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL Abstract#2249": {
            "url": "http://cancerres.aacrjournals.org/content/72/8_Supplement/2249",
            "year": "2012",
            "name": "Abstract 2249: Mutations to the GSK3β regulatory region of CTNNB1 increase TCF transcription activity and are resistant to degradation by GSK3β",
            "abstractNumber": "2249",
            "meeting": "Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL",
            "doi": "10.1158/1538-7445.AM2012-2249",
            "journalName": "Cancer Research",
            "displayName": "AACR 2012 (abstract 2249)"
        },
        "Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA Abstract#73": {
            "url": "https://cancerres.aacrjournals.org/content/75/15_Supplement/73",
            "year": "2015",
            "name": "Abstract 73: Targeting KDR mutations in lung adenocarcinoma",
            "abstractNumber": "73",
            "meeting": "Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA",
            "doi": "10.1158/1538-7445.AM2015-73",
            "journalName": "Cancer Research",
            "displayName": "AACR 2015 (abstract 73)"
        },
        "Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; November 5-9, 2015; Boston, MA Abstract#B27": {
            "url": "https://mct.aacrjournals.org/content/14/12_Supplement_2/B27",
            "year": "2015",
            "name": "Abstract B27: A phase I dose escalation study of the MDM2 inhibitor DS-3032b in patients with advanced solid tumors and lymphomas",
            "abstractNumber": "B27",
            "meeting": "Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; November 5-9, 2015; Boston, MA",
            "doi": "10.1158/1535-7163.TARG-15-B27",
            "journalName": "Molecular Cancer Therapeutics",
            "displayName": "AACR 2015 (abstract B27)"
        },
        "Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA Abstract#892": {
            "url": "https://cancerres.aacrjournals.org/content/76/14_Supplement/892",
            "year": "2016",
            "name": "Abstract 892: Functional characterization of EIF1AX mutations in thyroid cancer predicts for gain of function by increasing translational rate with concomitant derepression of upstream inputs from mTOR",
            "abstractNumber": "892",
            "meeting": "Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA",
            "doi": "10.1158/1538-7445.AM2016-892",
            "journalName": "Cancer Research",
            "displayName": "AACR 2016 (abstract 892)"
        },
        "Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA Abstract#3667": {
            "url": "https://cancerres.aacrjournals.org/content/76/14_Supplement/3667",
            "year": "2016",
            "name": "Abstract 3667: Potential role of DUSP4 as a tumor suppressor in pancreatic cancer",
            "abstractNumber": "3667",
            "meeting": "Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA",
            "doi": "10.1158/1538-7445.AM2016-3667",
            "journalName": "Cancer Research",
            "displayName": "AACR 2016 (abstract 3667)"
        },
        "Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA Abstract#LB-150": {
            "url": "https://cancerres.aacrjournals.org/content/76/14_Supplement/LB-150",
            "year": "2016",
            "name": "Abstract LB-150: A truncated ARID5B protein generated by a frame-shift mutation leads to aggressiveness of endometrial cancer",
            "abstractNumber": "LB-150",
            "meeting": "Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA",
            "doi": "10.1158/1538-7445.AM2016-LB-150",
            "journalName": "Cancer Research",
            "displayName": "AACR 2016 (abstract LB-150)"
        },
        "Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC Abstract#156": {
            "url": "http://cancerres.aacrjournals.org/content/77/13_Supplement/156",
            "year": "2017",
            "name": "Abstract 156: Preclinical characterization of GDC-0077, a specific PI3K alpha inhibitor in early clinical development",
            "abstractNumber": "156",
            "meeting": "Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC",
            "doi": "10.1158/1538-7445.AM2017-156",
            "journalName": "Cancer Research",
            "displayName": "AACR 2017 (abstract 156)"
        },
        "Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC Abstract#694": {
            "url": "https://cancerres.aacrjournals.org/content/77/13_Supplement/694",
            "year": "2017",
            "name": "Abstract 694: TK-216: a novel, first-in-class, small molecule inhibitor of EWS-FLI1 in early clinical development, for the treatment of Ewing Sarcoma",
            "abstractNumber": "694",
            "meeting": "Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC",
            "doi": "10.1158/1538-7445.AM2017-694",
            "journalName": "Cancer Research",
            "displayName": "AACR 2017 (abstract 694)"
        },
        "Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC Abstract#CT046": {
            "url": "https://cancerres.aacrjournals.org/content/77/13_Supplement/CT046",
            "year": "2017",
            "name": "Abstract CT046: Phase I dose escalation study of the CDK4/6 inhibitor palbociclib in combination with the MEK inhibitor PD-0325901 in patients with RAS mutant solid tumors",
            "abstractNumber": "CT046",
            "meeting": "Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC",
            "doi": "10.1158/1538-7445.AM2017-CT046",
            "journalName": "Cancer Research",
            "displayName": "AACR 2017 (abstract CT046)"
        },
        "Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC Abstract#DDT02-01": {
            "url": "https://cancerres.aacrjournals.org/content/77/13_Supplement/DDT02-01",
            "year": "2017",
            "name": "Abstract DDT02-01: Discovery of GDC-0077, a highly isoform selective inhibitor of PI3Kα that promotes selective loss of mutant-p110α",
            "abstractNumber": "DDT02-01",
            "meeting": "Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC",
            "doi": "10.1158/1538-7445.AM2017-DDT02-01",
            "journalName": "Cancer Research",
            "displayName": "AACR 2017 (abstract DDT02-01)"
        },
        "Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC Abstract#1850": {
            "url": "https://cancerres.aacrjournals.org/content/77/13_Supplement/1850",
            "year": "2017",
            "name": "Abstract 1850: Development of a NOTCH1 loss of function and PIK3CA mutant transgenic model of HNSCC",
            "abstractNumber": "1850",
            "meeting": "Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC",
            "doi": "10.1158/1538-7445.AM2017-1850",
            "journalName": "Cancer Research",
            "displayName": "AACR 2017 (abstract 1850)"
        },
        "Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL Abstract#3359": {
            "url": "https://cancerres.aacrjournals.org/content/78/13_Supplement/3359",
            "year": "2018",
            "name": "Abstract 3359: Elucidating the oncogenic mechanism of the TAZ-CAMTA1 and YAP-TFE3 fusion proteins",
            "abstractNumber": "3359",
            "meeting": "Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL",
            "doi": "10.1158/1538-7445.AM2018-3359",
            "journalName": "Cancer Research",
            "displayName": "AACR 2018 (abstract 3359)"
        },
        "Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL Abstract#1786": {
            "url": "https://cancerres.aacrjournals.org/content/72/8_Supplement/1786",
            "year": "2012",
            "name": "Abstract 1786: Characterization of the inhibitory capacity of EMD1214063, a novel small molecule inhibitor of the MET hepatocyte growth factor receptor on a panel of MET mutated variants",
            "abstractNumber": "1786",
            "meeting": "Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL",
            "doi": "10.1158/1538-7445.AM2012-1786",
            "journalName": "Cancer Research",
            "displayName": "AACR 2012 (abstract 1786)"
        },
        "Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL Abstract#LB-122": {
            "url": "https://cancerres.aacrjournals.org/content/72/8_Supplement/LB-122",
            "year": "2012",
            "name": "Abstract LB-122: A phase I dose escalation study of NVP-BGJ398, a selective pan FGFR inhibitor in genetically preselected advanced solid tumors",
            "abstractNumber": "LB-122",
            "meeting": "Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL",
            "doi": "10.1158/1538-7445.AM2012-LB-122",
            "journalName": "Cancer Research",
            "displayName": "AACR 2012 (abstract LB-122)"
        },
        "Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA Abstract#CT103": {
            "url": "https://cancerres.aacrjournals.org/content/74/19_Supplement/CT103",
            "year": "2014",
            "name": "Abstract CT103: Clinical safety and activity in a phase I trial of AG-221, a first in class, potent inhibitor of the IDH2-mutant protein, in patients with IDH2 mutant positive advanced hematologic malignancies",
            "abstractNumber": "CT103",
            "meeting": "Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA",
            "doi": "10.1158/1538-7445.AM2014-CT103",
            "journalName": "Cancer Research",
            "displayName": "AACR 2014 (abstract CT103)"
        },
        "Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA Abstract#CT228": {
            "url": "https://cancerres.aacrjournals.org/content/74/19_Supplement/CT228",
            "year": "2014",
            "name": "Abstract CT228: A phase II study of afatinib (A) in patients (pts) with metastatic human epidermal growth factor receptor (HER2)-positive trastuzumab (T) refractory esophagogastric (EG) cancer",
            "abstractNumber": "CT228",
            "meeting": "Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA",
            "doi": "10.1158/1538-7445.AM2014-CT228",
            "journalName": "Cancer Research",
            "displayName": "AACR 2014 (abstract CT228)"
        },
        "Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA Abstract#CT231": {
            "url": "https://cancerres.aacrjournals.org/content/75/15_Supplement/CT231",
            "year": "2015",
            "name": "Abstract CT231: A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with estrogen receptor+ HER2-, advanced/metastatic breast cancer",
            "abstractNumber": "CT231",
            "meeting": "Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA",
            "doi": "10.1158/1538-7445.AM2015-CT231",
            "journalName": "Cancer Research",
            "displayName": "AACR 2015 (abstract CT231)"
        },
        "Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA Abstract#CT322": {
            "url": "https://cancerres.aacrjournals.org/content/75/15_Supplement/CT322",
            "year": "2015",
            "name": "Abstract CT322: DNA repair defects and antitumor activity with PARP inhibition: TOPARP, a phase II trial of olaparib in metastatic castration resistant prostate cancer",
            "abstractNumber": "CT322",
            "meeting": "Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA",
            "doi": "10.1158/1538-7445.AM2015-CT322",
            "journalName": "Cancer Research",
            "displayName": "AACR 2015 (abstract CT322)"
        },
        "Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA Abstract#2631": {
            "url": "https://cancerres.aacrjournals.org/content/76/14_Supplement/2631",
            "year": "2016",
            "name": "Abstract 2631: Restrictions on access to systemic therapy limit the application of whole genome sequencing in clinical care",
            "abstractNumber": "2631",
            "meeting": "Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA",
            "doi": "10.1158/1538-7445.AM2016-2631",
            "journalName": "Cancer Research",
            "displayName": "AACR 2016 (abstract 2631)"
        },
        "Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA Abstract#CT005": {
            "url": "https://cancerres.aacrjournals.org/content/76/14_Supplement/CT005",
            "year": "2016",
            "name": "Abstract CT005: Phase I study of RAF dimer inhibitor BGB-283 in patients with B-RAF or K-RAS/N-RAS mutated solid tumors",
            "abstractNumber": "CT005",
            "meeting": "Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA",
            "doi": "10.1158/1538-7445.AM2016-CT005",
            "journalName": "Cancer Research",
            "displayName": "AACR 2016 (abstract CT005)"
        },
        "Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA Abstract#LB21": {
            "url": "https://cancerres.aacrjournals.org/content/76/14_Supplement/LB-214",
            "year": "2016",
            "name": "Abstract LB-214: FASN inhibitor TVB-2640 shows pharmacodynamic effect and evidence of clinical activity in KRAS-mutant NSCLC patients in a phase I study",
            "abstractNumber": "LB21",
            "meeting": "Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA",
            "doi": "10.1158/1538-7445.AM2016-LB-214",
            "journalName": "Cancer Research",
            "displayName": "AACR 2016 (abstract LB21)"
        },
        "Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC Abstract#CT002": {
            "url": "https://cancerres.aacrjournals.org/content/77/13_Supplement/CT002",
            "year": "2017",
            "name": "Abstract CT002: A Phase IB study of RAF dimer inhibitor BGB-283 in patients with B-RAF or K-RAS/N-RAS mutated solid tumors",
            "abstractNumber": "CT002",
            "meeting": "Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC",
            "doi": "10.1158/1538-7445.AM2017-CT002",
            "journalName": "Cancer Research",
            "displayName": "AACR 2017 (abstract CT002)"
        },
        "Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC Abstract#CT001": {
            "url": "https://cancerres.aacrjournals.org/content/77/13_Supplement/CT001",
            "year": "2017",
            "name": "Abstract CT001: Neratinib in HER2 or HER3 mutant solid tumors: SUMMIT, a global, multi-histology, open-label, phase 2 \"basket\" study",
            "abstractNumber": "CT001",
            "meeting": "Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC",
            "doi": "10.1158/1538-7445.AM2017-CT001",
            "journalName": "Cancer Research",
            "displayName": "AACR 2017 (abstract CT001)"
        },
        "Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC Abstract#CT152": {
            "url": "https://cancerres.aacrjournals.org/content/77/13_Supplement/CT152",
            "year": "2017",
            "name": "Abstract CT152: Phase I dose- and regimen-finding study of NVP-HDM201 in pts with advanced TP53 wt acute leukemias",
            "abstractNumber": "CT152",
            "meeting": "Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC",
            "doi": "10.1158/1538-7445.AM2017-CT152",
            "journalName": "Cancer Research",
            "displayName": "AACR 2017 (abstract CT152)"
        }
    }
}
